MedPath

Levobupivacaine

Generic Name
Levobupivacaine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H28N2O
CAS Number
27262-47-1
Unique Ingredient Identifier
A5H73K9U3W
Background

Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted

pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure to an anesthetic. Regardless, allergic reactions may also occur - although only rarely.

Indication

For the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management

Associated Conditions
Pain
Associated Therapies
Local Anaesthesia therapy, Lumbar epidural anesthesia therapy

Serratus-intercostal Plane Block Versus Quadratus Lumborum Block in Nephrectomy: Randomized Study

Completed
Conditions
Kidney Injury
Interventions
Device: ultrasound device
Drug: Levobupivacaine
First Posted Date
2020-06-16
Last Posted Date
2024-03-07
Lead Sponsor
Hospital Medina del Campo
Target Recruit Count
126
Registration Number
NCT04431388
Locations
🇪🇸

María Teresa Fernandez, Valladolid, VA, Spain

Effect of Fentanyl With Topical Levobupivacaine With Nasal Packing in Endoscopic Nasal Surgery

Phase 2
Conditions
Analgesia During Removal of Nasal Pack After Nasal Surgery
Interventions
First Posted Date
2020-06-01
Last Posted Date
2021-08-20
Lead Sponsor
Assiut University
Target Recruit Count
75
Registration Number
NCT04410588
Locations
🇪🇬

Wael, Assiut, Asyut, Egypt

Dexmedetomidine or Fentanyl as Additives to Epidural Levobupivacaine in Painless Labor

Phase 4
Completed
Conditions
Dexmedetomidine
Levobupivacaine
Painless Labor
Epidural Analgesia
Fentanyl
Interventions
First Posted Date
2020-05-21
Last Posted Date
2022-03-28
Lead Sponsor
Tanta University
Target Recruit Count
90
Registration Number
NCT04397406
Locations
🇪🇬

Tanta University Hospitals, Tanta, Gharbiya, Egypt

Prospective RCT Lidocaine & Levobupivacaine on Block Dynamics After Subparaneural Popliteal Sciatic Nerve Block

Phase 4
Recruiting
Conditions
Musculoskeletal Diseases or Conditions
Interventions
First Posted Date
2020-05-21
Last Posted Date
2023-09-25
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
40
Registration Number
NCT04397484
Locations
🇭🇰

Prince of Wales Hospital, Shatin, New Territories, Hong Kong

Post Tonsillectomy Analgesia Comparison After Surgery Site Spray of Local Anesthesics

Not Applicable
Completed
Conditions
Analgesia
Interventions
First Posted Date
2020-03-27
Last Posted Date
2020-03-27
Lead Sponsor
University of Liege
Target Recruit Count
44
Registration Number
NCT04325113
Locations
🇧🇪

Javillier, Liège, Belgium

Aalgesic Efficacy of Erector -Spinae Technique With Levobupvicaine in Patients Undergoing Upper Abdominal Cancer Surgery

Phase 1
Conditions
Erector Spinae Block Analgesia
Interventions
First Posted Date
2020-03-19
Last Posted Date
2020-03-19
Lead Sponsor
South Egypt Cancer Institute
Target Recruit Count
30
Registration Number
NCT04315454
Locations
🇪🇬

South Egypt Cancer Institute, Assiut, Egypt

Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery

Phase 2
Conditions
Analgesia
Breast Cancer
Interventions
Procedure: Ultrasound (US) bi-level erector spinae block
Drug: levobupivacaine
Drug: Ketamine
Drug: Magnesium Sulfate
First Posted Date
2020-02-19
Last Posted Date
2022-04-19
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT04275661
Locations
🇪🇬

south Egypt Cancer Institute Assiut University, Assiut, Egypt

Safety and Efficacy of Magnesium Sulphate as an Adjuvant to Levobupivacaine in Ultra-sound Guided Transversus Abdominis Plan Block in Pediatric Abdominal Cancer Surgery

Phase 3
Recruiting
Conditions
Postoperative Pain
Interventions
Procedure: ultra-sound guided transversus abdominis plan block
Drug: magnesium sulphate& levobupivacaine
Drug: Levobupivacaine
First Posted Date
2019-06-07
Last Posted Date
2023-04-19
Lead Sponsor
South Egypt Cancer Institute
Target Recruit Count
10
Registration Number
NCT03979599
Locations
🇪🇬

south Egypt cancer institute, Assiut, Egypt

MORphine Use in the Fascia Iliaca Compartment Block With UltraSound

Phase 4
Terminated
Conditions
Morphine
Analgesia
Humans
Pain Management
Anesthetics, Local
Pain
Anesthesia, Local
Fascia
Emergency Medicine
Analgesia, Patient-Controlled
Interventions
Drug: Placebo
Drug: Levobupivacaine
Drug: Acetaminophen
Drug: Morphine
Procedure: Fascia Iliaca Compartment Block with Levobupivacaine
Procedure: Fascia Iliaca Compartment Block with placebo
First Posted Date
2019-02-19
Last Posted Date
2021-05-06
Lead Sponsor
Zuyderland Medisch Centrum
Target Recruit Count
55
Registration Number
NCT03846102
Locations
🇳🇱

Zuyderland Medisch Centrum, Heerlen, Zuid Limburg, Netherlands

The Effect of Different Degree of Temperature on Levobupivacaine Spinal Anesthesia

Not Applicable
Conditions
Spinal Anesthetic Toxicity
Interventions
First Posted Date
2018-12-31
Last Posted Date
2019-01-02
Lead Sponsor
Mansoura University Hospital
Target Recruit Count
120
Registration Number
NCT03790163
Locations
🇪🇬

Adham Elgeidi, Mansourah, Dakahliah, Egypt

© Copyright 2025. All Rights Reserved by MedPath